Radioligand/Enzalutamide Improves PSA-PFS in Metastatic CRPC

"This is the first randomized trial combining an androgen receptor signaling inhibitor, enzalutamide, with ¹⁷⁷Lu-PSMA-617. It provides strong evidence for an enhanced anti-cancer effect with the combination of enzalutamide and ¹⁷⁷Lu-PSMA-617 based on the primary end point, PSA-PFS," according to Louise Emmett, MD, FRACP.

Patients with metastatic castration-resistant prostate cancer (mCRPC) experienced improvements in prostate-specific antigen (PSA) progression-free survival (PFS) when treated with enzalutamide (Xtandi) in combination with ¹⁷⁷Lu-PSMA-617 (lutetium Lu 177 vipivotide tetraxetan; Pluvicto) vs enzalutamide alone, according to interim data from the phase 2 ENZA-p study (NCT04419402) presented at the 2023 European Society for Medical Oncology Congress (ESMO).¹

“This is the first randomized trial combining an androgen receptor signaling inhibitor, enzalutamide, with ¹⁷⁷Lu-PSMA-617. It provides strong evidence for an enhanced anti-cancer effect with the combination of enzalutamide and ¹⁷⁷Lu-PSMA-617 based on the primary end point, PSA-PFS,” said Louise Emmett, MD, FRACP, during an oral presentation of the findings at the ESMO meeting. Emmett is the director of theranostics and nuclear medicine at St. Vincent’s Hospital in Sydney, Australia.

Data from the study showed a median PSA-PFS of 13 months with the combination therapy compared with 7.8 months with enzalutamide alone (HR, 0.43; 95% CI, 0.29-0.63; P = .00001). Median radiographic PFS was 16 months with the combination therapy compared with 12 months for enzalutamide alone (HR, 0.67; 95% CI, 0.44-1.01).¹

Further, PSA 50% (decrease ≥50% from baseline) response rates were 93% (77/83) in the combination arm, compared with 68% (54/79) for enzalutamide alone (P < .001). PSA 90% (decrease ≥90% from baseline) response rates were 78% (65/83) among those in the combination arm compared with 37% (29/79) among those who received enzalutamide alone (P < .001).¹

In total, the ENZA-p study included 162 patients with mCRPC. Patients were randomly assigned 1:1 to 160 mg of enzalutamide alone (n = 79) or 160 mg enzalutamide plus 7.5 GBq ¹⁷⁷Lu-PSMA-617 (n = 83) delivered in 2 or 4 doses. Those included in the combination therapy arm underwent 2 doses with ¹⁷⁷Lu-PSMA-617 with SPECT with 2 additional doses for those with persistent PSMA-positive disease detected at 92-day follow-up. In total, 81% of patients in the combination arm received 4 doses of ¹⁷⁷Lu-PSMA-617.¹

Emmett commented in the presentation, “We used 2 to 4 doses of Lu-PSMA in the ENZA-p trial, but 2 to 6 doses may further improve progression-free survival, particularly in those patients who have a high proportion of androgen persistent clones.”

The primary end point of the study was PSA-PFS. Secondary end points included radiological PFS, PSA50%, PSA90%, adverse events (AEs), and overall survival (OS). Median follow-up among all patients included in the study was 20 months.

Serious AEs were reported in 35% (28/79) of patients who received enzalutamide alone, compared with 33% (27/81) of patients who received enzalutamide with ¹⁷⁷Lu-PSMA-617. Grade 4 or 5 AEs were reported among 4% (3/79) of patients in the enzalutamide monotherapy arm, compared with 6% (8/81) of patients in the combination arm.¹

In the presentation conclusion, Emmett noted, “I think this is going to become more important as we move this radiation treatment earlier in the disease paradigm to hormone sensitive prostate cancer. It [has] the potential to reduce toxicity by only administering if persistent PSMA-avid disease is present on the PSMA-PET or SPECT images.”

Emmett also added that there is planned follow-up of PFS and OS in the study until July 2024.

Reference

1. Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901). Presented at the European Society of Medical Oncology (ESMO) Congress. October 20-24, 2023. Madrid, Spain. Abstract LBA84